<unk> , sold under the brand name Ngenla, is a medication for the treatment of growth hormone deficiency.<unk>  is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal. The most common side effects include reactions at the site of injection, headache, and fever.<unk>  was approved for medical use in Australia in November 2021, and in the European Union in February 2022.
Somatrogon
Thiotepa
Somatrem
Histrelin
Somatostatin
Bryostatin
Incretin
Ghrelin